SERUM CYSTATIN C FOR RISK STRATIFICATION IN PATIENTS WITH PREDIABETES

The aim of the investigation is to study the value of Cystatin-C among patients with prediabetes for risk stratification. Material and methods of the study. Our study included 55 people aged 18 to 65 years, including 35 men with an average age of 54.3±3.2 years and 20 women with an average age of 51.1±2.1 years. The study was conducted at the Andijan Regional Endocrinology Dispensary. The control group consisted of 20 healthy people. Research methods: included general clinical methods, biochemical tests (fasting blood glucose level and 2 hours after a meal, glycated hemoglobin, bilirubin, both direct and indirect, ALT, AST, PTI, coagulogram, C-reactive protein, urea, creatinine, lipid spectrum, Cystatin-C), hormonal studies (if necessary, insulin and C-peptide levels in the blood) and instrumental methods: ECG, ultrasound of the endocrine glands and internal organs, chest X-ray and others. Research results. Prediabetes is a risk factor for ASCVD (prediabetes: CI: 1.08–1.15; P < 0.001), chronic kidney disease (prediabetes: CI: 1.02–1.14; P < 0.001; ), and heart failure (prediabetes: CI: 1.01–1.14; P = 0.03; ). Compared with hemoglobin A1c (HbA1c) levels less than 5.0%, covariate-adjusted risks were significantly increased for ASCVD with HbA1c greater than 5.4%, chronic kidney disease greater than 6.2%, and heart failure greater than 7.0 In the same way, the average values ​​of CRP and Cystatin-C were significantly increased in comparison with the control group (p < 0.005). Conclusions: Cystatin C can be used as an early biomarker of chronic kidney disease (CKD) and is associated with prediabetes. It can help identify patients with preclinical kidney disease who are at increased risk of developing chronic kidney disease. Elevated cystatin C levels can detect CKD even in its early stages, when other markers such as creatinine have not yet changed significantly.